The lowered ARR and revenue guidance signals slowing growth momentum, likely pressuring the stock near-term. Watch for Q3 ARR ($524M-$528M) and revenue ($145M-$148M) execution; if new products like Genesis and Guardian fail to re-accelerate growth, further downside is possible. The raised EBITDA target provides a floor but does not offset the top-line miss.
Price Chart
Executive Summary
Cellebrite reported Q2 2026 non-GAAP EPS of $0.11, missing consensus of $0.11 by -2.5%, and revenue of $131.1M, slightly below the $131.9M consensus. The company lowered its full-year 2026 ARR and revenue guidance due to longer sales cycles and slower Inseyets expansions, while raising its adjusted EBITDA target. CEO transition to Shiven Ramji adds uncertainty, making this a mixed-to-bearish report with lowered top-line expectations offset by margin discipline.
Key Financial Metrics
Key Facts
- Non-GAAP diluted EPS of $0.11 missed consensus of $0.11 (-2.5% miss).
- Revenue of $131.1M grew 16% YoY but slightly below $131.9M consensus.
- Full-year 2026 ARR guidance lowered to $550M-$560M (14%-16% growth) from prior expectations.
- Full-year 2026 revenue guidance lowered to $555M-$561M (17%-18% growth).
- Full-year 2026 adjusted EBITDA target raised to $153M-$159M (~28% margin).
- CEO transition: Shiven Ramji succeeds Thomas Hogan effective immediately.
- Q2 ARR of $507.8M grew 21% YoY but came in below expectations.
- Recurring revenue dollar-based net retention rate was 117%, up 2 pts QoQ.
- Free cash flow for trailing twelve months was $144.2M (28.0% margin).
Financial Impact
Full-year revenue guidance lowered by ~$10-15M from prior trajectory; ARR growth decelerating from 21% to 14-16% YoY; EBITDA target raised by ~$5-10M.
Risk Factors
- Slower-than-expected Inseyets conversions and elongated sales cycles may persist.
- New product adoption (Genesis, Guardian) may not materialize as quickly as anticipated.
- CEO transition introduces execution risk during a period of lowered guidance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302850249 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13G | $11.44 $11.15 | ▼ −2.58% | ▼ −1.09% | $12.23 (+6.91%) |
Oct 7, 2026 19d ago | 144 | $11.23 $10.83 | ▼ −3.52% | ▼ −2.54% | $12.23 (+8.95%) |
Aug 27, 2026 8w ago | Insider Cluster | $11.99 $11.45 | ▼ −4.50% | ▼ −4.61% | $12.23 (+2.00%) |
Aug 27, 2026 8w ago | Insider Cluster | $11.99 $11.45 | ▲ +4.50% | ▲ +4.61% | $12.23 (−2.00%) |
Aug 25, 2026 8w ago | Insider Cluster | $11.62 $11.62 | · 0.00% | ▲ +0.12% | $12.23 (+5.25%) |
Aug 24, 2026 9w ago | Insider Cluster | $11.29 $11.85 | ▲ +4.96% | ▲ +5.50% | $12.23 (+8.33%) |
Aug 19, 2026 9w ago | 144 | $11.24 $11.62 | ▲ +3.38% | ▲ +3.77% | $12.23 (+8.81%) |
Aug 13, 2026 10w ago | Insider Cluster | $11.14 $11.05 | ▼ −0.81% | ▲ +0.56% | $12.23 (+9.78%) |
Aug 13, 2026 10w ago | 6-K | $11.14 $11.05 | ▼ −0.81% | ▲ +0.56% | $12.23 (+9.78%) |
Aug 13, 2026 10w ago | 6-K | $10.80 $11.31 | ▼ −4.72% | ▼ −6.69% | $12.23 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers